VIVUS Reports First Quarter 2009 Financial Results and ...(2008 and periodic reports filed with the...)

    CONTACT:

    VIVUS, Inc.
    Timothy E. Morris
    Chief Financial Officer
    650-934-5200

    Investor Relations: The Trout Group
                        Brian Korb
                        646-378-2923

    Media Relations:    Pure Communications, Inc.
                        Sheryl Seapy
                        949-608-084

                                     VIVUS, Inc.
                   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                      (in thousands, except per share amounts)

                                                  Three Months Ended
                                             March 31,           March 31,
                                                 2009                2008
                                           (unaudited)         (unaudited)
     Revenue:
       US product, net                           $893              $1,088
       International product                      293                 554
       License and other revenue               21,046              21,046

          Total revenue                        22,232              22,688

     Operating expenses:
       Cost of goods sold and manufacturing     2,603               2,787
       Research and development                20,069              23,371
       Selling, general and administrative      5,411               4,252

          Total operating expenses             28,083              30,410

     Loss from operations                      (5,851)             (7,722)

       Interest (expense) income, net of
        other-than-temporary loss on
        impaired securities                      (952)                635

     Loss before provision for income taxes    (6,803)             (7,087)

     Provision for income taxes                    (6)                 (5)

       
'/>"/>
SOURCE  VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 
Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update